Symbols

MNKD

Mannkind·NASDAQ

--(--)

MNKD fundamentals

MNKD Q4 2025 Earnings

Mannkind (MNKD) released its earnings on Feb 26, 2026: revenue was 111.95M (YoY +45.82%), beat estimates; EPS was -0.05 (YoY -266.67%), missed estimates.

Revenue / YoY

111.95M

+45.82%

EPS / YoY

-0.05

-266.67%

Report date

Feb 26, 2026

MNKD Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 revenue $112 million (+46% YoY), driven by FUROSCIX (+91% YoY) and Afrezza (+22% YoY)
Strategic Shift: $200+ million annual run rate outside UT, up from $3.8 million in 2018
Pipeline Momentum: MNKD-201 Phase II launch Q2 2026, Afrezza pediatric PDUFA May 29
Financial Strength: $350 million guaranteed from UT DPI over 36 months, non-GAAP adj. net income $1.5 million Q4
Growth Catalysts: FUROSCIX autoinjector July 2026, Afrezza pediatric launch H2 2026, MNKD-201 Phase Ib data H2 2026

Earnings

EPS

Revenue

Revenue & Expenses

MNKD has released its 2025 Q4 earnings report, with revenue of 111.95M, reflecting a YoY change of 45.82%, and net profit of -15.95M, showing a YoY change of -314.87%. The Sankey diagram below clearly presents MNKD's revenue sources and cost distribution.

Key Indicators

Mannkind (MNKD) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Mannkind (MNKD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Mannkind (MNKD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Mannkind (MNKD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown